Relacorilant Patent Expiration
Relacorilant was first introduced by Corcept Therapeutics Inc
Relacorilant Patents
Given below is the list of patents protecting Relacorilant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lifyorli (copackaged) | US12152028 | Methods Of Preparing Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | Dec 22, 2041 | Corcept Therap |
| Lifyorli (copackaged) | US11285145 | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 | May 26, 2041 | Corcept Therap |
| Lifyorli (copackaged) | US12589094 | Concomitant Administration Of Glucocorticoid Receptor Modulator Relacorilant And Paclitaxel, A Dual Substrate Of Cyp2C8 And Cyp3A4 | May 26, 2041 | Corcept Therap |
| Lifyorli (copackaged) | US11464764 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Apr 14, 2040 | Corcept Therap |
| Lifyorli (copackaged) | US11925626 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Dec 18, 2039 | Corcept Therap |
| Lifyorli (copackaged) | US12514849 | Pharmaceutical Formulations Containing Relacorilant, A Heteroaryl-Ketone Fused Azadecalin Compound | Dec 18, 2039 | Corcept Therap |
| Lifyorli (copackaged) | US10456392 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US11576907 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US8859774 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
| Lifyorli (copackaged) | US9273047 | Heteroaryl-Ketone Fused Azadecalin Glucocorticoid Receptor Modulators | May 24, 2033 | Corcept Therap |
Relacorilant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Relacorilant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | Corcept Therapeutics | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2 |